Capricor Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Capricor Therapeutics (CAPR).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

7Buy

2Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$31Upside to Avg. PT+242.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 14, 2026	B. Riley Securities	Madison El-Saadi	Upgrade	Neutral→Buy	$5→$21
Sep 1, 2026	Piper Sandler	Edward Tenthoff	Upgrade	Neutral→Overweight	$2→$25
Aug 14, 2026	Cantor Fitzgerald	Kristen Kluska	Upgrade	Neutral→Overweight	$4→$28
Jul 31, 2026	Jones Trading	Catherine Novack	Downgrade	Buy→Hold	—
Jul 30, 2026	Piper Sandler	Edward Tenthoff	Downgrade	Overweight→Neutral	$58→$2
Jul 30, 2026	Cantor Fitzgerald	Kristen Kluska	Downgrade	Overweight→Neutral	$62→$4
Jul 30, 2026	HC Wainwright & Co.	Joseph Pantginis	Downgrade	Buy→Neutral	—
May 13, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$60
Mar 13, 2026	B. Riley Securities	Madison El-Saadi	PT Raise	Buy	$50→$63
Mar 13, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$45→$58
Mar 13, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$60
Mar 10, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$60
Dec 15, 2025	B. Riley Securities	Madison El-Saadi	PT Raise	Buy	$21→$50
Dec 10, 2025	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$20→$45
Dec 8, 2025	Oppenheimer	Leland Gershell	PT Raise	Outperform	$22→$54
Dec 4, 2025	Maxim Group	Jason McCarthy	PT Raise	Buy	$25→$50
Dec 3, 2025	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$24→$60
Nov 12, 2025	Roth Capital	Boobalan Pachaiyappan	PT Raise	Buy	$12→$13
Sep 25, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$24
Sep 11, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$24

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21

B. Riley Securities analyst Madison El-Saadi upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Buy and raises the price target from $5 to $21.

Benzinga Newsdesk

PRO
Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25

Piper Sandler analyst Edward Tenthoff upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $2 to $25.

Benzinga Newsdesk

This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.

Avi Kapoor

PRO
Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28

Cantor Fitzgerald analyst Kristen Kluska upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $3.5 to $28.

Benzinga Newsdesk

PRO
Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2

Piper Sandler analyst Edward Tenthoff downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $58 to $2.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $3.5

Cantor Fitzgerald analyst Kristen Kluska downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $62 to $3.5.

Benzinga Newsdesk

Capricor Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Capricor Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21

PRO
Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25

This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

PRO
Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28

PRO
Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2

PRO
Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $3.5

People Also Watch

People Also Watch

Capricor Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Capricor Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21

PROPiper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25

This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

PROCantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28

PROPiper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2

PROCantor Fitzgerald Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $3.5

People Also Watch

People Also Watch

PRO
B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21

PRO
Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25

PRO
Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28

PRO
Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2

PRO
Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $3.5